- Dec 12, 2014
NCT02252172 : Phase 3 - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma - MAIA STUDY
The MAIA Study NCT02252172: Phase 3: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in...
475
- Dec 12, 2014
NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS
CENTAURUS A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma The purpose of this study...
166
- Dec 11, 2014
NCT02136134: Phase 3 - Daratumumab Plus Bortezomib & Dexa in relapsed Myeloma MMY3004 (CASTOR) Study
The CASTOR Trial Dara Vd DVd NCT02136134: Phase 3: Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants...
472
- Dec 9, 2014
NCT02312258: Phase 3: TOURMALINE-MM4 - Oral Ixazomib Maintenance Therapy in NDMM-TIE
TOURMALINE-MM4 Trial NCT02312258: Phase 3: A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple...
64
- Dec 12, 2013
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) The purpose of this study is to assess the...
80
- Dec 12, 2012
NCT01568866: Phase 3 - Carfilzomib and Dex Vs Bortezomib & Dex for Relapsed Myeloma (ENDEAVOR)
The ENDEAVOR Trial KD Vs Vd The primary objective of this study was to compare progression-free survival in patients with multiple...
451